EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk of first and second primary keratinocyte cancers in relation to treatment of rheumatoid arthritis with JAKi, TNFi, and non-TNFi bDMARDs—a Swedish nationwide study

Viking Huss, Hannah Bower, Martin Björklund, Karin Hellgren, Thomas Frisell, Benedicte Delcoigne, Daniela Di Giuseppe, Johan Askling, ARTIS group

Annals of the Rheumatic Diseases · 2026-08 · 85 (8) · 1520-1529

DOI: 10.1016/j.ard.2026.02.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-08. Verfasst von Viking Huss und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Rheumatology, Theme Inflammation and Ageing, …. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Janus Kinase Inhibitors, Tumor Necrosis Factor Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sweden's Innovation Agency, Nordforsk, Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aims to assess the risks of primary and second primary keratinocyte cancers (KCs) in patients with rheumatoid arthritis (RA) and in relation to treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic disease-modifying antirheumatic drugs. METHODS: Nationwide cohort study of patients treated with Janus kinase inhibitors (JAKi), tumour necrosis factor inhibitor (TNFi), or non-TNFi bDMARDs, using data from the Swedish Rheumatology Quality Register linked to other registers including the National Cancer Register, 2012 through 2023. Adjusted hazard ratios (HRs) were estimated via Cox regression using TNFi as reference. RESULTS: We identified 21,756 unique patients with RA. Based on 155 incident KC with JAKi, 458 with non-TNFi and 766 with TNFi, the HR for JAKi vs TNFi was 1.39 (1.16-1.68), corresponding to 1 extra KC case per every 244 patients per year. For non-TNFi vs TNFi, the HR was 0.96 (0.86-1.08). By subtype, the HR for JAKi vs TNFi was 1.41 (1.13-1.75) for basal cell carcinoma and 1.49 (1.09-2.05) for squamous cell carcinoma (SCC). For abatacept vs etanercept, the HR for SCC was 1.48 (1.11-1.97). The HR for a second primary KC was 1.31 (0.94-1.82) for JAKi and 0.94 (0.75-1.17) for non-TNFi bDMARD vs TNFi. CONCLUSIONS: Patients treated with JAKi have an elevated risk of KC compared with patients treated with TNFi. Although the class of non-TNFi bDMARDs is not associated with increased KC risk, we repeated a drug-specific signal of increased risk for SCC with abatacept.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsJanus Kinase InhibitorsTumor Necrosis Factor InhibitorsKeratinocytesSkin NeoplasmsNeoplasms, Second PrimaryHumansFemaleSwedenMaleMiddle AgedAgedRegistriesAdultCarcinoma, Squamous CellNon-Melanoma Skin NeoplasmsRisk FactorsIncidence

Substanzen

Antirheumatic AgentsJanus Kinase InhibitorsTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Rheumatology, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden. Electronic address:…
  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Rheumatology, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden.

Förderung

  • Sweden's Innovation Agency
  • Nordforsk
  • Swedish Research Council
  • Karolinska Institutet
  • Swedish Cancer Society

Zitieren

APA

Huss, V., Bower, H., Björklund, M., Hellgren, K., Frisell, T., Delcoigne, B., Di Giuseppe, D., Askling, J., & ARTIS group (2026). Risk of first and second primary keratinocyte cancers in relation to treatment of rheumatoid arthritis with JAKi, TNFi, and non-TNFi bDMARDs—a Swedish nationwide study. Annals of the Rheumatic Diseases, 85(8), 1520-1529. https://doi.org/10.1016/j.ard.2026.02.015

Vancouver

Huss V, Bower H, Björklund M, Hellgren K, Frisell T, Delcoigne B, et al. Risk of first and second primary keratinocyte cancers in relation to treatment of rheumatoid arthritis with JAKi, TNFi, and non-TNFi bDMARDs—a Swedish nationwide study. Annals of the Rheumatic Diseases. 2026;85(8):1520-1529. doi:10.1016/j.ard.2026.02.015

BibTeX
@article{Huss2026,
  author = {Huss, Viking and Bower, Hannah and Björklund, Martin and Hellgren, Karin and Frisell, Thomas and Delcoigne, Benedicte and Di Giuseppe, Daniela and Askling, Johan and ARTIS group, ARTIS group},
  title = {Risk of first and second primary keratinocyte cancers in relation to treatment of rheumatoid arthritis with JAKi, TNFi, and non-TNFi bDMARDs—a Swedish nationwide study},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {8},
  pages = {1520--1529},
  doi = {10.1016/j.ard.2026.02.015}
}
Kostenlos starten →